On March, 8 WallStreet awaited OncoSec Medical Incorporated (NASDAQ:ONCS)’s earnings report, RTT reports. The earnings per share diference is $0.06 or 25.00 % up from last years number. Previous year: $-0.24; Analysts forcast: $-0.18. 28.57 % negative EPS growth is what Wall Street’s forecasts after $-0.14 reported EPS previous quarter. The stock decreased 1.03% or $0.006 during the last trading session, hitting $0.575.Currently OncoSec Medical Incorporated is downtrending after 48.82% change in last March 1, 2018. ONCS has also 515,970 shares volume. ONCS underperformed by 48.82% the S&P500.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States.The firm is worth $37.09 million. The Company’s lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer.Currently it has negative earnings. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.

For more OncoSec Medical Incorporated (NASDAQ:ONCS) news brought out briefly go to: Seekingalpha.com, Streetinsider.com, Streetinsider.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “OncoSec: The Underlying Science Of ImmunoPulse Powers A Potential Winner – Seeking Alpha” brought out on April 18, 2018, “OncoSec (ONCS) Says Intratumoral IL-12 In Metastatic TNBC Selected For Oral Poster Presentation at AACR – StreetInsider.com” on March 15, 2018, “Oncosec Medical (ONCS) Appoints Sara M. Bonstein as CFO and COO – StreetInsider.com” with a publish date: July 16, 2018, “Vericel leads healthcare gainers; OncoSec Medical tops losers – Seeking Alpha” and the last “OncoSec up 8% premarket on new TAVO data – Seeking Alpha” with publication date: November 29, 2018.